Merck & Co., Inc.’s anticancer checkpoint inhibitor Keytruda (pembrolizumab) has maintained its position at the top of the league table of the world’s best-selling drugs in the second quarter. It attained supremacy for the first time in the first quarter of 2023 as COVID-19 product sales began declining and AbbVie Inc.’s Humira (adalimumab), which for many years had dominated the list, suffered a steep drop after losing US market exclusivity and facing biosimilar competition from late January.
Key Takeaways
-
Gardasil 9 and Darzalex entered the list for the first time in Q2 2023.
-
Keytruda and Ozempic show strong consistent growth, with Ozempic expected to rise to second place in 2024
Combined sales of the top 10 best-selling drugs globally fell precipitously in the second quarter of 2023, from $46.3bn in the second quarter of 2022 to $32.8bn
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
